Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Feb 20, 2014 South San Francisco, CA, February 20, 2014 – Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointments of Derek Bertocci as Chief Financial Officer and John Smither as a member of the Board of D...
Jan 28, 2014 South San Francisco, CA, January 28, 2014 – Achaogen, a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission fo...
Sep 23, 2013 South San Francisco, CA, September 23, 2013 – Achaogen, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial of plazomicin in patients with serious multi-drug resistant (MDR) gram-negative bacterial infectio...
Apr 24, 2013 South San Francisco, CA, April 24, 2013 – Achaogen, Inc. today announced the award of a $60M contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a global Phase 3 superiority study that will evaluate the efficacy and safety of plazomicin in treating patien...
May 15, 2012 South San Francisco, CA, May 15, 2012 – Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults. Achaogen is developing plazomicin, a next...
Sep 28, 2011 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Achaogen, Inc., a biopharmaceutical company discovering and developing treatments for life-threatening, multi-drug resistant (MDR) Gram-negative bacterial infections, announced today that the company's board of directors has appointed Kenneth J. Hillan, M.B. Ch.B., the company’s ...
Mar 22, 2011 SOUTH SAN FRANCISCO, Calif., March 22, 2011 – Achaogen, Inc., a biopharmaceutical company discovering and developing antibiotics for the treatment of life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the hiring of Kenneth J. Hillan, M.B. Ch.B., as chief medical officer. Dr. Hillan will fill a ...
Sep 9, 2010 SOUTH SAN FRANCISCO, Calif., September 9, 2010 – Achaogen, a biopharmaceutical company and developing antibiotics to treat life-threatening, multi-drug resistant (MDR), today announced key upcoming data presentations involving its lead antibiotic ...
Aug 30, 2010 SOUTH SAN FRANCISCO, Calif., August 30, 2010 – Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), wit...
Apr 7, 2010 SAN FRANCISCO, Calif., April 7 , 2010 – Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was ...
Page: FirstPrevious ...
13
NextLast
= add release to Briefcase